| Application of Multimodal MRI in Histological Grading and Prognostic Assessment of Rectal Cancer (NCT07269912) | Sichuan Cancer Hospital and Research Institute | 2027-11-01 |
| Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial (NCT07775040) | Sichuan Cancer Hospital and Research Institute | 2026-08-20 |
| Preoperative Decision-Making in Patients With Pulmonary Nodules Suspected of Lung Cancer (NCT07590596) | Sichuan Cancer Hospital and Research Institute | 2026-05-01 |
| Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC (NCT07561983) | Sichuan Cancer Hospital and Research Institute | 2026-05-01 |
| Construction and Empirical Research of the Applicable Baduanjin Protocol for Patients With Colorectal Cancer Enterostomy (NCT07172087) | Sichuan Cancer Hospital and Research Institute | 2025-09-01 |
| The Efficacy of Antegrade and Retrograde Enemas Management in Low Anterior Resection Syndrome and Improving the Rate of Ileostomy Reversal (NCT07082699) | Sichuan Cancer Hospital and Research Institute | 2025-07-20 |
| A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma (NCT07062484) | Sichuan Cancer Hospital and Research Institute | 2025-07-01 |
| Application of the sG8 Scale in Real-World Geriatric Oncology Patients (NCT06939764) | Sichuan Cancer Hospital and Research Institute | 2025-05-16 |
| Retrograde and Antegrade Enema for Prevention of LARS After LAR: a Randomized Controlled Trial (NCT06717854) | Sichuan Cancer Hospital and Research Institute | 2025-03-25 |
| Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery (NCT06860685) | Sichuan Cancer Hospital and Research Institute | 2025-03-01 |
| Development and Verification of a Screening Tool for Comprehensive Geriatric Assessment of Elderly Tumor Patients (NCT06761534) | Sichuan Cancer Hospital and Research Institute | 2025-02-05 |
| Intravenous Lidocaine Infusion Reduce Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy (NCT06138041) | Sichuan Cancer Hospital and Research Institute | 2025-02-01 |
| Reduced Dissemination of Tumor Cells With Primary Ligation of the Inferior Mesenteric Vein in Rectal Cancer Patients. (NCT05807646) | Sichuan Cancer Hospital and Research Institute | 2025-01-01 |
| Neoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study (NCT06697938) | Sichuan Cancer Hospital and Research Institute | 2024-11-18 |
| Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC (NCT06532591) | Sichuan Cancer Hospital and Research Institute | 2024-08-01 |
| DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma (NCT04834674) | Sichuan Cancer Hospital and Research Institute | 2024-07-01 |
| A Cohort Establishment Study of Total Management of Ovarian Cancer (NCT06018935) | Sichuan Cancer Hospital and Research Institute | 2024-06-17 |
| Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients (NCT06007586) | Sichuan Cancer Hospital and Research Institute | 2024-05-31 |
| Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients (NCT06361589) | Sichuan Cancer Hospital and Research Institute | 2024-05-01 |
| Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer (NCT06244537) | Sichuan Cancer Hospital and Research Institute | 2024-04-01 |
| Effect of 3D-printed Reconstruction System in Size of Left DLT (NCT06258954) | Sichuan Cancer Hospital and Research Institute | 2024-04-01 |
| Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma (NCT06102447) | Sichuan Cancer Hospital and Research Institute | 2023-11-01 |
| 3D-printed Reconstruction Automated Matching System Predicts Size of Double-lumen Tube: a Prospective Double-blinded Randomized Controlled Trial (NCT05899270) | Sichuan Cancer Hospital and Research Institute | 2023-11-01 |
| Association Between Surgical Timing and Route of Total Hysterectomy After LEEP and Perioperative Risk in Patients With Cervical HSIL (NCT06325592) | Sichuan Cancer Hospital and Research Institute | 2023-10-01 |
| A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis (NCT06410040) | Sichuan Cancer Hospital and Research Institute | 2023-08-20 |
| Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer (NCT05173272) | Sichuan Cancer Hospital and Research Institute | 2023-07-24 |
| Shared Decision Making in Patients With Lung Cancer (NCT05191485) | Sichuan Cancer Hospital and Research Institute | 2023-02-22 |
| MRI - Guided Adaptive RadioTHerapy for Dysphagia in Head and Neck Cancer (NCT05831917) | Sichuan Cancer Hospital and Research Institute | 2023-01-17 |
| The Effect of Nitozumab in the Treatment of Head and Neck Squamous Cell Carcinoma (NCT05831930) | Sichuan Cancer Hospital and Research Institute | 2023-01-17 |
| A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer (NCT05641506) | Sichuan Cancer Hospital and Research Institute | 2022-12-01 |
| Sintilimab Plus NCT or NCRT Versus NCRT for ESCC (NCT05244798) | Sichuan Cancer Hospital and Research Institute | 2022-11-01 |
| A RCT on the Preventive Effect of HFNC on Postoperative Pulmonary Complications in Patients With Gynecologic Neoplasms (NCT05526534) | Sichuan Cancer Hospital and Research Institute | 2022-11-01 |
| A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer (NCT05444374) | Sichuan Cancer Hospital and Research Institute | 2022-10-01 |
| Low-dose Radiotherapy and Neoadjuvant Chemotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma (NCT05503914) | Sichuan Cancer Hospital and Research Institute | 2022-08-01 |
| Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC (NCT05394233) | Sichuan Cancer Hospital and Research Institute | 2022-06-01 |
| A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer (NCT05028504) | Sichuan Cancer Hospital and Research Institute | 2022-05-10 |
| Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma (NCT05508347) | Sichuan Cancer Hospital and Research Institute | 2022-04-20 |
| Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma (NCT05292027) | Sichuan Cancer Hospital and Research Institute | 2022-03-26 |
| Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer (NCT05472467) | Sichuan Cancer Hospital and Research Institute | 2021-12-21 |
| Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC (NCT05189730) | Sichuan Cancer Hospital and Research Institute | 2021-07-01 |
| Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma (NCT04725448) | Sichuan Cancer Hospital and Research Institute | 2021-04-06 |
| Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. (NCT05044728) | Sichuan Cancer Hospital and Research Institute | 2021-04-01 |
| Dose-painting Radiation for LA-NSCLC (NCT05031533) | Sichuan Cancer Hospital and Research Institute | 2021-01-01 |
| Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma (NCT04602013) | Sichuan Cancer Hospital and Research Institute | 2020-10-11 |
| TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC (NCT04518852) | Sichuan Cancer Hospital and Research Institute | 2020-09-14 |
| Surveillance of Peripheral Blood of Lymphocyte and Immunocyte in Neoadjuvant Therapy Patients With Esophageal Squamous Cell Carcinoma (pLINE) (NCT04440332) | Sichuan Cancer Hospital and Research Institute | 2020-07-01 |
| Quantitative Assessment of Blood Supply in the Gastic Conduit With Fluorescence Angiography for Esophageal Reconstruction (NCT04229524) | Sichuan Cancer Hospital and Research Institute | 2020-06-01 |
| Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC (NCT04371796) | Sichuan Cancer Hospital and Research Institute | 2020-05-10 |
| Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (NCT04177797) | Sichuan Cancer Hospital and Research Institute | 2020-03-20 |
| Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC (NCT04133337) | Sichuan Cancer Hospital and Research Institute | 2019-11-01 |
| Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC (NCT03389256) | Sichuan Cancer Hospital and Research Institute | 2018-12-30 |
| Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC (NCT03706287) | Sichuan Cancer Hospital and Research Institute | 2018-12-06 |
| Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC (NCT03703596) | Sichuan Cancer Hospital and Research Institute | 2018-10-16 |
| PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial (NCT05520814) | Sichuan Cancer Hospital and Research Institute | 2018-08-01 |
| Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer (NCT03262545) | Sichuan Cancer Hospital and Research Institute | 2017-08-27 |
| Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation (NCT03153358) | Sichuan Cancer Hospital and Research Institute | 2017-06-02 |
| Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma (NCT03180476) | Sichuan Cancer Hospital and Research Institute | 2017-04-01 |
| Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy (NCT03135977) | Sichuan Cancer Hospital and Research Institute | 2017-03-01 |
| Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma (NCT02399306) | Sichuan Cancer Hospital and Research Institute | 2014-09-01 |
| Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (NCT02123381) | Sichuan Cancer Hospital and Research Institute | 2014-04-01 |
| The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC） (NCT02076477) | Sichuan Cancer Hospital and Research Institute | 2014-01-01 |
| Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer (NCT01623102) | Sichuan Cancer Hospital and Research Institute | 2013-02-01 |
| Outcomes of Smoker and Drinker With Esophageal Squamous Cell Carcinoma After Esophagectomy (NCT06269341) | Sichuan Cancer Hospital and Research Institute | 2010-02-01 |
| Effect of Cervical Paraesophageal Lymph Node Metastasis Versus Supraclavicular Lymph Node Metastasis on the Overall Survival of Patients With Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study (NCT06165094) | Sichuan Cancer Hospital and Research Institute | 2009-01-01 |